Recombinant Human ADT Protein，His

ADT (Antibody-Drug Conjugates) represent a promising approach in targeted cancer therapy, combining the specificity of monoclonal antibodies with the cytotoxic potential of therapeutic drugs. The objective of ADT research is to enhance the efficacy and reduce the systemic toxicity typically associated with conventional chemotherapy. The first generation of ADTs showed significant potential but faced challenges, including off-target effects and limited therapeutic windows. Recent advancements in protein engineering, linker technology, and drug payloads have led to the development of next-generation ADTs aimed at improving tumor targeting and overcoming resistance mechanisms. Furthermore, the integration of novel biomarkers in patient stratification is transforming ADT design, enabling personalized treatment regimens that optimize outcomes. Researchers are increasingly focused on understanding the mechanisms of action, resistance pathways, and the tumor microenvironment's influence on ADT efficacy. This research is crucial for addressing clinical challenges and broadening the application of ADTs across various cancer types. As a result, the exploration of ADT recombinant proteins is at the forefront of oncology, highlighting the need for continued innovation in protein design and therapeutic strategies to maximize the potential of this targeted therapy in clinical settings.